Showing results (301-310 of 6,284) with videos related to
Sort By:
Pageof 629
Diabetes, Obesity & Metabolism|November 26, 2009
The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistanceS Kirkham, R Akilen, S Sharma, et al.Diabetes, Obesity & Metabolism|November 26, 2009
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care settingD I Brixner, C McAdam-Marx, X Ye, et al.Diabetes, Obesity & Metabolism|November 26, 2009
Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) studyM J Davies, R Donnelly, A H Barnett, et al.Diabetes, Obesity & Metabolism|March 7, 2001
Testosterone and leptin in a group of Chinese with and without diabetesW Y Ng, K F Lui, A C ThaiDiabetes, Obesity & Metabolism|November 3, 2017
Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trialsKang Chen, Deying Kang, Miao Yu, et al.Diabetes, Obesity & Metabolism|November 7, 2017
A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetesThorsten Siegmund, Nikolaos Tentolouris, Søren T Knudsen, et al.Diabetes, Obesity & Metabolism|November 21, 2017
Systemic use of antibiotics and risk of diabetes in adults: A nested case-control study of Alberta's Tomorrow ProjectMing Ye, Paula J Robson, Dean T Eurich, et al.Diabetes, Obesity & Metabolism|October 13, 2017
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesisKaren M Hallow, Gabriel Helmlinger, Peter J Greasley, et al.Diabetes, Obesity & Metabolism|October 13, 2017
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisonsNiels B Dalsgaard, Tina Vilsbøll, Filip K KnopDiabetes, Obesity & Metabolism|April 1, 2018
Use of the waist-to-height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE-ON studyKarin Rådholm, John Chalmers, Toshiaki Ohkuma, et al.Pageof 629